title: How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.
abstract: Oestrogen deficiency increases the rate of bone remodelling which, in association with a negative remodelling balance (resorption exceeding formation), results in impaired bone architecture, mass and strength. Current anti-osteoporotic drugs act on bone remodelling by inhibiting bone resorption or by promoting its formation. An alternative therapeutic approach is based on the concept of inducing opposite effects on bone resorption and formation. One therapeutic agent, strontium ranelate, was shown to induce opposite effects on bone resorption and formation in pre-clinical studies and to reduce fracture risk in postmenopausal osteoporotic patients. How strontium ranelate acts to improve bone strength in humans remains a matter of debate, however. This review of the most recent pre-clinical and clinical studies is a critical analysis of strontium ranelate's action on bone resorption and formation and how it increases bone mass, microarchitecture and strength in postmenopausal osteoporotic women.
authors.affiliation: Laboratory of Osteoblast Biology and Pathology, INSERM, U606, Paris 75475, France. pierre.marie@inserm.fr
authors.forename: P J
authors.initials: PJ
authors.lastname: Marie
authors.forename: D
authors.initials: D
authors.lastname: Felsenberg
authors.forename: M L
authors.initials: ML
authors.lastname: Brandi
mesh_terms: D000368:Aged; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects*; D001862:Bone Resorption / Q000517:prevention & control*; D005260:Female; D006801:Humans; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000503:physiopathology / Q000517:prevention & control*; D058866:Osteoporotic Fractures / Q000517:prevention & control; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
references.citation: J Bone Miner Res. 2006 Apr;21(4):536-42
references.pmid: 16598373
references.citation: J Bone Miner Res. 2003 Jun;18(6):1082-7
references.pmid: 12817762
references.citation: J Bone Miner Res. 1993 May;8(5):607-15
references.pmid: 8511988
references.citation: Bone. 2001 Aug;29(2):176-9
references.pmid: 11502480
references.citation: J Bone Miner Res. 2010 Apr;25(4):891-900
references.pmid: 20437609
references.citation: J Bone Miner Res. 2009 Aug;24(8):1358-68
references.pmid: 19338452
references.citation: Osteoporos Int. 2010 Jun;21(6):1031-6
references.pmid: 19813043
references.citation: Bone. 2010 Apr;46(4):1038-42
references.pmid: 20026265
references.citation: Osteoporos Int. 2009 Aug;20(8):1417-28
references.pmid: 19096745
references.citation: J Bone Miner Res. 2004 Dec;19(12):2012-20
references.pmid: 15537445
references.citation: Osteoporos Int. 2009 Apr;20(4):653-64
references.pmid: 18763010
references.citation: Osteoporos Int. 2010 Nov;21(11):1889-97
references.pmid: 19957162
references.citation: J Biol Chem. 2010 Aug 13;285(33):25251-8
references.pmid: 20554534
references.citation: N Engl J Med. 2004 Jan 29;350(5):459-68
references.pmid: 14749454
references.citation: J Bone Miner Res. 2007 Sep;22(9):1419-25
references.pmid: 17547534
references.citation: Osteoporos Int. 2003;14 Suppl 3:S25-34
references.pmid: 12730784
references.citation: Br J Pharmacol. 2009 Aug;157(7):1291-300
references.pmid: 19563530
references.citation: J Clin Endocrinol Metab. 2007 Aug;92(8):3076-81
references.pmid: 17566094
references.citation: Bone. 2009 Dec;45(6):1059-64
references.pmid: 19679207
references.citation: FASEB J. 2006 Dec;20(14):2562-4
references.pmid: 17077282
references.citation: Bone. 1996 Jun;18(6):517-23
references.pmid: 8805991
references.citation: J Bone Miner Res. 1996 Sep;11(9):1302-11
references.pmid: 8864905
references.citation: J Bone Miner Res. 2004 May;19(5):862-9
references.pmid: 15068510
references.citation: Biochem Biophys Res Commun. 2007 Apr 6;355(2):307-11
references.pmid: 17300752
references.citation: J Bone Miner Res. 2007 Jul;22(7):1002-10
references.pmid: 17371157
references.citation: Calcif Tissue Int. 2010 Jan;86(1):82-9
references.pmid: 19960189
references.citation: Osteoporos Int. 2009 Jul;20(7):1101-6
references.pmid: 19266136
references.citation: Biochem Biophys Res Commun. 2004 Oct 29;323(4):1184-90
references.pmid: 15451421
references.citation: Eur J Pharmacol. 2002 Aug 16;450(1):11-7
references.pmid: 12176103
references.citation: Sci Signal. 2008 Sep 02;1(35):ra1
references.pmid: 18765830
references.citation: Metabolism. 2002 Jul;51(7):906-11
references.pmid: 12077740
references.citation: Curr Med Res Opin. 2007 Dec;23(12):3041-5
references.pmid: 17967221
references.citation: Bone. 2003 Jul;33(1):115-23
references.pmid: 12919706
references.citation: Osteoporos Int. 2009 Oct;20(10):1663-73
references.pmid: 19153678
references.citation: Metabolism. 2004 Apr;53(4):532-7
references.pmid: 15045704
references.citation: J Clin Endocrinol Metab. 2005 May;90(5):2816-22
references.pmid: 15728210
references.citation: J Bone Miner Res. 2008 Feb;23(2):215-22
references.pmid: 17922612
references.citation: Bone. 2008 Jan;42(1):129-38
references.pmid: 17945546
references.citation: Mol Pharmacol. 2010 Oct;78(4):569-76
references.pmid: 20584969
references.citation: J Biol Chem. 2009 Jan 2;284(1):575-584
references.pmid: 18927086
references.citation: Endocrinology. 1999 Dec;140(12):5883-93
references.pmid: 10579354
references.citation: J Bone Miner Res. 2010 May;25(5):968-75
references.pmid: 19874195
references.citation: Osteoporos Int. 2008 Dec;19(12):1813; author reply 1815-7
references.pmid: 18795218
references.citation: J Cell Mol Med. 2009 Aug;13(8B):2189-99
references.pmid: 20141614
references.citation: Bone. 2008 Jun;42(6):1131-6
references.pmid: 18378206
references.citation: Osteoporos Int. 2011 Jan;22(1):289-97
references.pmid: 20204596
references.citation: Osteoporos Int. 2003 Jan;14(1):2-12
references.pmid: 12577179
references.citation: Bone. 2010 May;46(5):1436-41
references.pmid: 20116464
references.citation: Sci Signal. 2008 Sep 02;1(35):pe40
references.pmid: 18765829
references.citation: J Clin Invest. 2005 Dec;115(12):3318-25
references.pmid: 16322775
references.citation: Rheumatol Int. 2010 Aug;30(10):1341-8
references.pmid: 20512336
references.citation: J Orthop Res. 2010 May;28(5):578-82
references.pmid: 20014319
references.citation: Arthritis Rheum. 2008 Jun;58(6):1687-95
references.pmid: 18512789
references.citation: Curr Opin Rheumatol. 2006 Jun;18 Suppl 1:S11-5
references.pmid: 16735840
references.citation: Hum Reprod. 2005 Nov;20(11):3053-61
references.pmid: 16055456
references.citation: Biochem Pharmacol. 2007 Aug 1;74(3):438-47
references.pmid: 17531955
references.citation: Osteoporos Int. 2010 Jun;21(6):1037-8; author reply 1039-40
references.pmid: 20107976
references.citation: Osteoporos Int. 2008 Sep;19(9):1331-41
references.pmid: 18385919
references.citation: J Orthop Res. 2010 Sep;28(9):1208-14
references.pmid: 20196084
references.citation: Osteoporos Int. 2003;14 Suppl 3:S2-8
references.pmid: 12730770
references.citation: J Biol Chem. 1997 Oct 10;272(41):25899-906
references.pmid: 9325322